Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Clasificación en acciones #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Precio por acción
$70.50
Última sincronización: 2025-11-14
Capitalización bursátil
$7.33B
Cambio (1 día)
0.00%
Cambio (1 año)
116.32%
País
US
Comercio Metsera, Inc. (MTSR)

Categoría

Historial de rendimiento por dividendo de Metsera, Inc. (MTSR)
Rendimiento por dividendo (TTM) de Metsera, Inc. (símbolo bursátil: MTSR) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Metsera, Inc. (MTSR) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH